Exclusive Interview: The Hydroponics Company’s Dual Focus on Canada and Australia
November 27th, 2017
News, Top News
CFN Media’s Rachelle Gordon recently spoke with The Hydroponics Company Ltd. (ASX: THC) CEO David Radford about the company’s parallel focus on Canada and Australia and its long-term plans to grow through both organic growth and acquisitions.
The company was recently issued a Medicinal Cannabis License from the Office of Drug Control under the medical cannabis provisions of the Narcotics Drugs Act of 1976 in Australia, which was a major milestone in the company’s goal to supply high quality products to Australians. Currently, the company is completing a facility in Queensland for research and growing operations that will be key to monetizing Canndeo’s (a wholly owned subsidiary of The Hydroponics Company Ltd.) cannabis strain IP and leveraging its experience in breeding, growing, and developing Cannabis Sativa.
Rachelle Gordon: You are an international portfolio-based business capitalizing on the global cannabis markets by providing resources to cultivators but also through the development and delivery of your own cultivated medical cannabis, tell us about this model?
David Radford: The model is designed to give investors exposure to the rapidly growing Canadian market through our wholly owned subsidiary-Crystal Mountain, and in parallel to enable them to share in the upside from the legalisation of medicinal cannabis in Australia.
Where and how you are sourcing medical cannabis, where is the company (through its subsidiary) cultivating on its own and which global markets are you serving?
As has been announced, the Company has entered into an agreement with Endoca for the supply of high quality medicinal cannabis products. This gives us the ability to supply the Australian market whilst the Company is waiting upon finalisation of its licensing to allow production and manufacturing of local product. The company is focused in the Australian medicinal cannabis market.
Which assets do you own and control, including licenses and research capabilities in order to deliver on your overall strategy?
The 2 Medicinal Cannabis licenses owned by the Company allow for R&D and Growing of medicinal cannabis. The Company is waiting upon Government approval for its final licence, the Manufacturing licence. This will give THC all 3 available licences in Australia
In October, THC was issued a Medicinal Cannabis Licence by the Office of Drug Control, which is the second of three licences required to commence cultivating and manufacturing medicinal cannabis at our Australian facilities. We expect the final licence, a Manufacturing Licence, will be issued in the near term and have invested substantially in our Australian facilities to enable a rapid transition to commercialisation
THC has invested in R&D and growing facilities in Australia and is able to work with the cultivation and selection of specific strains of medicinal cannabis
Explain the high level monetization strategy that includes proprietary cannabis strain IP, breeding and other expertise?
The Australian market is predominantly focused on the CBD market in the short term. THC through its subsidiary Canndeo has the capability to select and grow specific strains of Cannabis sativa, with plant breeding rights on 6 strains of plants. Initial discussions have been held with several companies in Canada to explore the opportunities for R&D projects in Australia, which would be able to qualify for the Australian Government’s R&D tax credit-currently 43c/$ for locally conducted R&D.
What is the high level plan to seize on the projected growth of the global cannabis industries?
Exposure to the Canadian market provides THC with an opportunity to share in the growth of the market through their “picks and shovels” business-Crystal Mountain. Developing new medicinal cannabis products through Clinical Trials.
Finally, as an investor in THC, which markets and segments are THC investors exposed to and how is their investment de-risked?
Canada: Expansion plans include both organic and acquisitive. Organic growth through the addition of new products and agencies to the Catalogue. Acquisitive growth once suitable targets have been identified.
Australia: Exposure to both Canadian and Australian markets. Australia will develop through innovative solutions to building the market.
About The Hydroponics Company
The Hydroponics Company (ASX: THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on the development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients. We aim to capitalise on the surging global cannabis market, generating significant near term value through our strategic assets, rapidly expanding these core businesses in 2017 and beyond.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.